CN116507336B - 治疗pde iv介导的疾病或病症的方法 - Google Patents

治疗pde iv介导的疾病或病症的方法

Info

Publication number
CN116507336B
CN116507336B CN202180062221.XA CN202180062221A CN116507336B CN 116507336 B CN116507336 B CN 116507336B CN 202180062221 A CN202180062221 A CN 202180062221A CN 116507336 B CN116507336 B CN 116507336B
Authority
CN
China
Prior art keywords
disease
ear
formula
inflammatory
pdeiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180062221.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN116507336A (zh
Inventor
V·库普里维卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN116507336A publication Critical patent/CN116507336A/zh
Application granted granted Critical
Publication of CN116507336B publication Critical patent/CN116507336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180062221.XA 2020-09-10 2021-09-10 治疗pde iv介导的疾病或病症的方法 Active CN116507336B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10
US63/076,774 2020-09-10
PCT/US2021/049870 WO2022056265A1 (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions

Publications (2)

Publication Number Publication Date
CN116507336A CN116507336A (zh) 2023-07-28
CN116507336B true CN116507336B (zh) 2026-01-02

Family

ID=78080507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062221.XA Active CN116507336B (zh) 2020-09-10 2021-09-10 治疗pde iv介导的疾病或病症的方法

Country Status (12)

Country Link
US (1) US12622915B2 (enExample)
EP (1) EP4210674A1 (enExample)
JP (2) JP7826294B2 (enExample)
KR (1) KR20230066350A (enExample)
CN (1) CN116507336B (enExample)
AU (1) AU2021338837A1 (enExample)
BR (1) BR112023004214A2 (enExample)
CA (1) CA3191177A1 (enExample)
CL (1) CL2023000648A1 (enExample)
IL (1) IL300628A (enExample)
MX (1) MX2023002539A (enExample)
WO (1) WO2022056265A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108848668A (zh) * 2015-12-24 2018-11-20 加利福尼亚大学董事会 Cftr调节剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
PL378245A1 (pl) 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
WO2007142929A2 (en) 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
US8080563B2 (en) * 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108848668A (zh) * 2015-12-24 2018-11-20 加利福尼亚大学董事会 Cftr调节剂及其使用方法

Also Published As

Publication number Publication date
AU2021338837A1 (en) 2023-04-06
WO2022056265A1 (en) 2022-03-17
JP2023541261A (ja) 2023-09-29
JP7826294B2 (ja) 2026-03-09
BR112023004214A2 (pt) 2023-04-11
CA3191177A1 (en) 2022-03-17
IL300628A (en) 2023-04-01
US20230364100A1 (en) 2023-11-16
KR20230066350A (ko) 2023-05-15
CN116507336A (zh) 2023-07-28
EP4210674A1 (en) 2023-07-19
CL2023000648A1 (es) 2023-10-13
JP2026102632A (ja) 2026-06-23
MX2023002539A (es) 2023-03-14
US12622915B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
JP7298928B2 (ja) ホスホジエステラーゼの阻害及びその関連障害のための治療剤
KR101563753B1 (ko) 피부 궤양의 치료 방법
CN106967070A (zh) 作为jak抑制剂的化合物
CN115873001B (zh) 一种基于蛋白水解靶向嵌合体技术(protac)的jak降解剂的新用途
TW425284B (en) A composition for treating and protecting a disorder in an organ or a tissue consisting phenylthiazole derivative
US20210113566A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US20260027073A1 (en) Use of small-molecule compound having naphthylamine structure
Yang et al. Multifunctional carbon quantum dots: iron clearance and antioxidation for neuroprotection in intracerebral hemorrhage mice
JP2025185105A (ja) タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
CN116507336A (zh) 治疗pdeiv介导的疾病或病症的方法
JP4589122B2 (ja) ホスホジエステラーゼ１０ａ阻害剤
US20210198266A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
EP2965755A1 (de) Verbindungen zur verwendung bei der behandlung von erkrankungen
EP3188759B1 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
JP2016508957A (ja) カンジダ等の病原微生物による疾患用の医薬組成物
CN119700700A (zh) 有效缓解痛风性关节炎并抑制复发的仿生化集成式纳米酶
Wang et al. Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma
KR20150035276A (ko) 라파마이신 및 미콜페놀산을 유효성분으로 포함하는 아토피 피부염 예방 및 치료용 조성물
TW202241392A (zh) 用以治療與嗜中性白血球激活失調及趨化相關之疾病的方法
Fraga et al. High hypoxia-inducible factor-1a expression genotype associated with Eastern Cooperative Oncology Group performance in head and neck squamous cell carcinoma
AbdAl-Salam et al. Adverse effects of moxifloxacin and flunixin meglumine and their combination on pregnant rats
HK40110887A (en) Composition with antiaging and antiinflammatory effects, and its preparation method and application
Ridzuan et al. Secretome of mesenchymal stem cells and its impact on Chronic Obstructive Pulmonary Disease
HK40036810A (en) Method of treatment and compositions comprising a dual pl3k delta-gamma kinase inhibitor and a corticosteroid
CN118846061A (zh) 肠道菌群代谢产物8-姜辣素的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant